ADGM

Adagio Medical Holdings, Inc.'s stock price has experienced significant fluctuations over the past six months. As of May 5, 2026, the share price was $0.98, a 22.22% decline from $1.26 on May 6, 2025, with a 52-week range between $0.74 and $2.58. In January 2025, the company announced waivers with investors following a financial misstatement and received a Nasdaq non-compliance notice, coinciding with a 90% stock decline. In late 2025, Adagio Medical completed enrollment for its FULCRUM-VT study, reported preliminary effectiveness results of 97%, and announced a private placement of up to $50 million. In April 2026, the company announced positive pivotal results for its vCLAS Ventricular Ablation System, received FDA IDE approval for its next-generation vCLAS, and participated in healthcare conferences.